Epstein-Barr Virus and Associated Diseases: Proceedings of the First International Symposium on Epstein-Barr Virus-Associated Malignant Diseases (Loutraki, Greece—September 24–28, 1984)P.H. Levine, D.V. Ablashi, G.R. Pearson, S.D. Kottaridis It has been slightly more than two decades since the Epstein-Barr virus (EBV) was discovered by Prof. M.A. Epstein and his colleagues at the University of Bristol in their search for the causative agent of Burkitt's lymphoma. For several years EBV was a "virus in search of a disease." The first documentation that EBV was pathogenic for humans was in 1969 when Drs. Gertrude and Werner Henle identified it as the causative agent for infectious mononucleosis. Seroepidemiologic and biochemical studies subsequently linked EBV to Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), and more recently to the X-linked lymphoproliferative syndrome. With its widespread pattern of infection and a predilection for producing clinical signs and symptoms in only certain individuals, EBV has provided a model for many other candidate oncogenic viruses, including papilloma viruses, herpes simplex, and HTLV/LAV. In 1975, an international workshop was sponsored by the National Cancer Institute to address the problem of EBV production, thus facilitating basic research on the virus. This proved to be the last international meeting on EBV for almost a decade. In the past, progress in both clinical and basic research on EBV has been presented in two types of international meetings, the international herpesvirus workshops devoted primarily to basic research on both human and animal herpesviruses, and the international symposia on NPC, in which EBV-related studies were interspersed with clinical, epidemiologic and other etiologic aspects of this important human neoplasm. |
Contents
| 18 | |
Immune Assessment of Patients with Chronic Active EBV | 34 |
Unusual Primary Tumors of Brain and Lungs Associated | 53 |
The Significance of Antibodies 73 333 | 73 |
Genetic Aspects of EBVAssociated Malignancies M Simons | 90 |
Pathology of EpsteinBarr Virus EBVAssociated Disease | 106 |
The Family Study Approach to Investigating the Role of | 131 |
An EBVAssociated Salivary Gland Cancer A P Lanier | 145 |
Study of Nucleosomal Organization of Chromatin in EBV | 345 |
Novel Biological Functions Associated with EpsteinBarr | 355 |
EBV DNA Content and Expression in Nasopharyngeal | 362 |
Transformation of Human Lymphocytes by Coinfection with | 373 |
EpsteinBarr VirusActivating Substances from Soil Y Ito | 383 |
Hydrocortisone Enhancement of both EBV Replication and | 392 |
Detection of EBNA and Rescue of | 402 |
Bacterially Synthesized EBNA as a Reagent for Enzyme | 426 |
Early Detection and IgA | 151 |
Evaluation of EpsteinBarr Virus Serologic Analysis in North | 164 |
Use of EpsteinBarr Virus Serology in the Diagnosis of | 180 |
An Analysis of the Relationship Between Clinical Pathology | 193 |
Fossa of Rosenmuller The Site for | 200 |
CarcinoEmbryonic Antigen CEA in | 207 |
Persistence and Expression of the EpsteinBarr Virus 221 | 219 |
An EpsteinBarr VirusDetermined Nuclear Antigen Encoded | 248 |
An EBV RNA with a Repetitive Spliced Structure | 256 |
Characterization of an EBVAssociated Protein Kinase | 267 |
Characterization of the Genes within the BamHI Fragment | 278 |
Effects of Tunicamycin on Binding of EpsteinBarr Virus | 289 |
Structure and Expression of the | 299 |
Antibody Response to EpsteinBarr | 307 |
The HostCell Range of the EpsteinBarr Virus R Glaser | 319 |
EpsteinBarr Virus EBV Growth Transformation is | 334 |
Antigenicity of | 436 |
Characterization of Two Forms of the 72000 MW EBNA and | 456 |
Localization of EpsteinBarr Virus Early Antigen EA by | 477 |
Identification of Multiple EpsteinBarr Virus Nuclear | 495 |
Cellular Immunity in EBV Infections J H Pope 511 | 510 |
T Cell Responses to EpsteinBarr Virus Infection | 525 |
In Vitro Immunogenicity of Human Lymphoid Tumour Cell | 553 |
Analysis of Intratumoral Lymphocyte Subsets in Patients | 572 |
Potential Usefulness of Isoprinosine as an Immunostimulating | 580 |
Prevention of EB VirusAssociated Malignant Diseases 603 | 601 |
A Perspective on Treatment of EBV Infection States | 619 |
Management of Nasopharyngeal Carcinoma A T Huang | 644 |
Treatment of Nasopharyngeal Carcinoma with the Antiviral | 660 |
The Teatment of Nasopharyngeal | 673 |
LIST OF PARTICIPANTS | 687 |
Other editions - View all
Epstein-Barr Virus and Associated Diseases P H Levine,D V Ablashi,G R Pearson No preview available - 1985 |
Common terms and phrases
Acad acid activity Acyclovir ADCC ALA GLY GLY antigen assay associated B-lymphocytes BamHI biopsy Burkitt's lymphoma Cancer cell lines cellular chromatin chromosome clinical cloned culture cytotoxicity detected disease early antigen EB virus EBNA EBV DNA EBV genome EBV infection EBV-associated EBV-specific EcoRI encoded epithelial cells Epstein Epstein-Barr virus DNA Epstein-Barr virus EBV expression fragment gene genetic genome GLY ALA GLY GLY GLY ALA Henle human hybridization IgA/VCA immune deficiency immunoblotting immunofluorescence immunoglobulin Immunol induced infectious mononucleosis Kieff Klein lymphoblastoid lymphoblastoid cell lines lymphocytes malignant membrane antigen monoclonal antibodies nasopharyngeal carcinoma Natl nitrocellulose normal NPC patients nuclear antigen Pearson polypeptide positive Proc protein purified Purtilo Raji cells reading frame region replication response sequence sera serologic serum specific studies suppressor suppressor cells syndrome T-cell Table tissue titers transfected transformation tumor viral genome virions Virol vitro